



## **Corporate Action Announcement**

Citibank, N.A., acting as unsponsored depositary bank, announces the following:

Date: March 24, 2016 Status: Final

Announcement For: Ratio Change

Company Name: ONO Pharmaceutical Co. Ltd.

Security Information Current Information: New Information:

Company: ONO Pharmaceutical Co. Ltd.

Ticker Symbol: OPHLY
CUSIP: 682736103
Country: Japan
Exchange: OTC
Ratio (ORD:ADR): 1:5

Ordinary Ticker: 4528 JP DTC Eligible: Yes

Ordinary ISIN: JP3197600004
DR ISIN: US6827361030
Custodian: Citibank Japan Ltd.

## **Announcement**

Notice is hereby given that, as a result of a five (5) for one (1) stock split, the ADS-to-Share ratio will be changed, effective as of the Effective Date, as follows:

1:3

Existing ADS-to-Share Ratio: 5 ADSs to 1 Share New ADS-to-Share Ratio: 3 ADSs to 1 Share

Effective Date: April 4, 2016



A distribution 200% will be made as a result of this ratio change (for every 1 ADS held as of the Record Date, 2 additional ADSs will be issued). No action on the part of Holders or Beneficial Owners is required. The CUSIP number for the ADS will remain the same.

The books of the Depositary will be closed for ADS issuances and cancellations from close of business in New York on March 31, 2016 through the close of business in New York on April 6, 2016.

## **Shareholder Services**

Questions may be directed to Shareholder Services toll free at 1-877-248-4237.

For further information on Citi Depositary Receipt Services, visit <a href="www.citi.com/dr">www.citi.com/dr</a>.

<sup>© 2016</sup> Citibank, N.A. All rights reserved. Citi and Arc Design is a registered service mark of Citigroup Inc. The above information is being provided solely for information purposes by Citi. At the time of publication, this information was believed to be accurate, but Citi makes no representation or warranty as to correctness of the information set forth above. The above information does not constitute a recommendation, solicitation or offer by Citi for the purchase or sale of any securities, nor shall this material be construed in any way as investment or legal advice or a recommendation, reference or endorsement by Citi.